The Royal Marsden Hospital is currently recruiting for a trial of adjuvant treatment for high-risk stage II melanoma (MK-3475-716/KEYNOTE-716) after surgical removal at the hospital.
This is a trial of immunotherapy with pembrolizumab for patients with Stage IIB or IIC melanoma which has been completely removed by wide local excision and sentinel node biopsy.
The aim of the study is to investigate whether the addition of pembrolizimab to surgery will reduce the rate of recurrence of melanoma, and the safety of the treatment. To do that, patients will be randomized to treatment or placebo. The trial is currently open at the Royal Marsden Hospital.